Affinivax is a clinical stage biotechnology company developing a next generation approach in vaccine technologies to design both preventive and therapeutic vaccines that provide broader protection against infectious and other immune mediated diseases.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $348.5M
Investors 6
| Date | Name | Website |
| 20.02.2021 | Logos Capi... | logoscapit... |
| - | Foresite C... | foresiteca... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Perceptive... | perceptive... |
| - | CARB-X | carb-x.org |
| - | Bain Capit... | baincapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.01.2021 | Series C | $226M | - |
| 24.04.2020 | Series B | $120M | - |
| 05.02.2016 | - | $2.5M | - |
Mentions in press and media 16
| Date | Title | Description |
| 01.06.2022 | Companies that thought turning a profit was hard last year aren’t going to like 2022 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. After a series of days in utter and complete COVID-positive isolation, yesterday was my re-introd... |
| 08.01.2021 | Affinivax Raises $226M in Series C Financing | Affinivax, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, closed a $226m Series C financing. The rou... |
| 08.01.2021 | T. Rowe Price Joins $226 Million Series C for Affinivax | Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS platform, today announced the closing of a $226 million Series C financing, co-led by new investors Rock Sprin... |
| 08.01.2021 | Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round | After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Nearly doubling that already im... |
| 08.01.2021 | Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round | After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Sponsored by Agilent Technologi... |
| 08.01.2021 | Daily funding roundup - January 8th, 2021 | SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M SilviaTerra: SilviaTerra is a San Francisco-based forestry company for organizations to exchange carbon offsets. SilviaTerra has raised $4.... |
| 08.01.2021 | Affinivax Announces $226 Million Series C Financing | Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS platform, today announced the closing of a $226 million Series C financing, co-led by new investors Rock Sprin... |
| 24.04.2020 | Affinivax Raises $120M to Advance Clinical Trials of Vaccines | Photo: Shutterstock Affinivax, a biotech startup out of Cambridge, announced Thursday it closed on a $120 million Series B round led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners. Th... |
| 23.04.2020 | Affinivax banks $120M to push vaccines against hospital-associated superbugs W h i t e p a p e r Weighing the Costs: | Affinivax, the company looking to unseat the world’s best-selling vaccine, has reeled in $120 million to advance its pipeline. But with its lead program—a Prevnar 13 challenger that covers 24 strains of pneumococcus—fully financed by a part... |
| 23.04.2020 | Affinivax Closes On $120M Series B As Biotech Takes Center Stage Globally | 6 Shares Email Facebook Twitter LinkedIn Biotech companies have not historically been thought of as “sexy,” but as the COVID-19 pandemic continues to impact the world, that might be changing. As evidence of that, Boston-based Affinivax toda... |
Show more